Addendum to ACERH Research Report No.7 Original statement: Entecavir is subsidised only as a second line therapy for patients who have failed

First Page		Document Content
Date: 2010-07-22 00:16:23 Bristol-Myers Squibb Entecavir Lamivudine Adefovir Hepatitis B Pharmaceutical Benefits Scheme Medicine Purines Chemistry Organic chemistry		Addendum to ACERH Research Report No.7 Original statement: Entecavir is subsidised only as a second line therapy for patients who have failed Add to Reading List Source URL: pandora.nla.gov.au Download Document from Source Website File Size: 268,68 KB Share Document on Facebook

	A Day in Life at BMS Welcome to A Day in Life at BMS where you will meet leaders from our R&D organization and learn more about research and development at Bristol-Myers Squibb, as well as network with our scientists. To DocID: 1vrK6 - View Document
	NoIN THE Supreme Court of the United States BRISTOL-MYERS SQUIBB COMPANY, PETITIONER, DocID: 1tuCc - View Document
	Bristol-Myers Squibb Co. v. Superior Court of Cal., San Francisco Cty) DocID: 1tut4 - View Document
	September 2003 USA Bristol-Myers Squibb Medical Imaging DocID: 1sKnx - View Document
	May 2003 Bristol-Myers Squibb Medical Imaging 331 Treble Cove Road N. Billerica, Massachusetts 01862 DocID: 1sC8T - View Document